A Multinational, Randomized, Double-Blind, Double-Dummy, Exploratory, Parallel Group, Dose-Ranging Phase II Study to Evaluate Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Several Intravenous Regimens of Factor Xa Inhibitor Otamixaban (XRP0673), in Comparison to Intravenous Unfractionated Heparin, in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention.
Latest Information Update: 03 Aug 2021
At a glance
- Drugs Otamixaban (Primary) ; Heparin
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Biomarker; Pharmacodynamics
- Acronyms SEPIA-PCI
- 15 Sep 2006 Status change
- 15 Sep 2006 The expected completion date for this trial is now .
- 25 Nov 2005 New trial record.